-

Insulet to Participate in 44th Annual J.P. Morgan Healthcare Conference

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 11:15 a.m. (Pacific Time).

The live webcast and replay of the presentation will be accessible on the Insulet Investor Relations website: investors.insulet.com/events.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit Insulet.com or omnipod.com.

©2025 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved.

Contacts

Investor Relations:
Clare Trachtman
Vice President, Investor Relations
(978) 218-0889
ctrachtman@insulet.com

Media:
Angela Geryak Wiczek
Senior Director, Corporate Communications
(978) 932-0611
awiczek@insulet.com

Insulet Corporation

NASDAQ:PODD

Release Versions

Contacts

Investor Relations:
Clare Trachtman
Vice President, Investor Relations
(978) 218-0889
ctrachtman@insulet.com

Media:
Angela Geryak Wiczek
Senior Director, Corporate Communications
(978) 932-0611
awiczek@insulet.com

More News From Insulet Corporation

For World Diabetes Day, Insulet Launches “Give Yourself the Freedom to” Campaign, Encouraging People with Diabetes to Prioritize Their Well-Being 

ACTON, Mass.--(BUSINESS WIRE)--In recognition of World Diabetes Day on November 14, 2026, Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its “Give Yourself the Freedom to” campaign designed to raise awareness of the often overlooked emotional and mental demands of living with diabetes and encourage people living with diabetes to prioritize their own well-being. “Living with d...

Insulet Reports Third Quarter 2026 Results

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its financial results for the three months ended September 30, 2026. Third Quarter Financial Highlights: Revenue of $842.0 million, up 19.2%, or 19.6% in constant currency, slightly above the high end of the Company’s guidance range of 17.5% - 19.5% at constant currency rates Total Omnipod revenue o...

Insulet to Participate in the 2026 Jefferies Global Healthcare Conference in London

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the 2026 Jefferies Global Healthcare Conference in London on Wednesday, November 18, 2026, at 10:30 a.m. (GMT). The live webcast and replay of the presentation will be accessible on the Insulet Investor Relations website: investors.insulet.com/events. About Insulet Corporation: Insulet Corpor...
Back to Newsroom